Clinical Trial Update: Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 trial evaluating a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants starting at ~2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV21 (21-valent pneumococcal conjugate vaccine) (pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pneumococcal Immunization | Phase 3 | Status: ACTIVE_NOT_RECRUITING